The role of CTGF in diabetic retinopathy.

Autor: Klaassen I; Ocular Angiogenesis Group, Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: i.klaassen@amc.uva.nl., van Geest RJ; Ocular Angiogenesis Group, Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Kuiper EJ; Ocular Angiogenesis Group, Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., van Noorden CJ; Ocular Angiogenesis Group, Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Schlingemann RO; Ocular Angiogenesis Group, Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Netherlands Institute for Neuroscience, Royal Academy of Sciences, Amsterdam, The Netherlands.

Publikováno v: Experimental eye research [Exp Eye Res] 2015 Apr; Vol. 133, pp. 37-48.

Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Autor: Pennock S; The Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, and the Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA., Kim D, Mukai S, Kuhnle M, Chun DW, Matsubara J, Cui J, Ma P, Maberley D, Samad A, Van Geest RJ, Oberstein SL, Schlingemann RO, Kazlauskas A

Publikováno v: The American journal of pathology [Am J Pathol] 2013 May; Vol. 182 (5), pp. 1659-70. Date of Electronic Publication: 2013 Apr 09.

Hemizygous deletion of CTGF/CCN2 does not suffice to prevent fibrosis of the severely injured kidney.

Autor: Falke LL; Department of Pathology, University Medical Center Utrecht, The Netherlands., Dendooven A, Leeuwis JW, Nguyen TQ, van Geest RJ, van der Giezen DM, Broekhuizen R, Lyons K, Stoop R, Kemperman H, Schlingemann R, Joles JA, Goldschmeding R

Publikováno v: Matrix biology : journal of the International Society for Matrix Biology [Matrix Biol] 2012 Sep-Oct; Vol. 31 (7-8), pp. 421-31.

Differential TGF-{beta} signaling in retinal vascular cells: a role in diabetic retinopathy?

Autor: Van Geest RJ; Ocular Angiogenesis Group, Departments of Ophthalmology and Cell Biology and Histology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Klaassen I, Vogels IM, Van Noorden CJ, Schlingemann RO

Publikováno v: Investigative ophthalmology & visual science [Invest Ophthalmol Vis Sci] 2010 Apr; Vol. 51 (4), pp. 1857-65. Date of Electronic Publication: 2009 Dec 03.

Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study.

Autor: van Geest RJ; Donders Institute of Ophthalmology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. r.j.vangeest@amc.uva.nl, Sasim IV, Koppeschaar HP, Kalmann R, Stravers SN, Bijlsma WR, Mourits MP

Publikováno v: European journal of endocrinology [Eur J Endocrinol] 2008 Feb; Vol. 158 (2), pp. 229-37.